Video

Dr. Aggarwal on ADT Intensification in Biochemically Relapsed Prostate Cancer

Author(s):

Rahul Aggarwal, MD

In Partnership With:

Rahul Aggarwal, MD, discusses the rationale for investigating androgen deprivation therapy intensification in biochemically relapsed prostate cancer.

Rahul Aggarwal, MD, developmental therapeutics specialist, genitourinary oncologist, the University of California Health (UCSF), UCSF Helen Diller Family Comprehensive Cancer Center, discusses the rationale for investigating androgen deprivation therapy (ADT) intensification in biochemically relapsed prostate cancer.

The phase 3 PRESTO study (NCT03009981) evaluated ADT alone vs ADT plus apalutamide (Erleada) vs ADT plus apalutamide, abiraterone acetate (Zytiga), and prednisone in men with biochemically recurrent prostate cancer and a prostate specific antigen (PSA) doubling time less than 9 months following radical prostatectomy.

Investigators evaluated intensified therapy on the backbone of ADT over a 52-week period in an effort to suppress PSA and enable longer treatment-free intervals, Aggarwal explains.

The top line interim analysis results for the primary end point of PSA progression-free survival (PFS) were presented at the 2022 ESMO Congress, Aggarwal continues. Patients treated in the 2 experimental arms featuring ADT plus apalutamide and ADT plus apalutamide, abiraterone, and prednisone experienced improved PSA PFS compared with patients who received ADT alone, Aggarwal concludes.

Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Related Content
FDA
November 21st 2024

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

The University of California San Francisco
November 11th 2024

UC Regents Approve UCSF Proton Therapy Center for Cancer Care

Here is your snapshot of all therapeutic options that the FDA approved in October 2024.
November 5th 2024

OncLive’s October Roundup of Key FDA Approvals in Oncology